Substance Abuse Research Center, Department of Psychiatry, Shiraz University of Medical Sciences, Shiraz, Iran.
Substance Abuse Research Center, Department of Psychiatry, Shiraz University of Medical Sciences, Shiraz, Iran.
Asian J Psychiatr. 2018 Dec;38:92-95. doi: 10.1016/j.ajp.2017.11.004. Epub 2017 Nov 7.
Escitalopram has some unique features among selective serotonin reuptake inhibitors. The aim of this survey is to compare the efficacy of escitalopram with sertraline on obsessive and compulsive symptoms in patients with Obsessive Compulsive Disorder (OCD).
In this 12-week double blind controlled randomized clinical trial, 57 patients with OCD were randomly allocated to receive escitalopram or sertraline. Yale Brown obsessive compulsive behavior scale (YBOCS) was used to assess the outcomes. Adverse effects were also recorded.
41 patients (20 in the escitalopram group and 21 in the sertraline group) completed the trial. In the escitalopram group 15 (70%) patients and in the sertraline group 16 (76.19%) patients showed more than 34% decrease in mean YBOCS score at the end of the trial (P=0.531). The two groups revealed significant decrease in YBOCS scores without significant difference (P=0.861) at week 12. No serious adverse effects were reported.
Our results demonstrated that escitalopram is as effective as sertraline in treatment of obsessions and compulsions in patients with OCD. However, it needs to be noted that our study is preliminary and larger double blind controlled studies are needed to confirm the results.
艾司西酞普兰在选择性 5-羟色胺再摄取抑制剂中具有一些独特的特征。本研究旨在比较艾司西酞普兰与舍曲林对强迫症患者强迫和强迫症状的疗效。
在这项为期 12 周的双盲对照随机临床试验中,57 例强迫症患者被随机分为艾司西酞普兰或舍曲林组。采用耶鲁-布朗强迫量表(YBOCS)评估疗效。同时记录不良反应。
41 例患者(艾司西酞普兰组 20 例,舍曲林组 21 例)完成了试验。艾司西酞普兰组 15 例(70%)和舍曲林组 16 例(76.19%)患者在试验结束时 YBOCS 评分平均下降超过 34%(P=0.531)。两组在第 12 周时 YBOCS 评分均显著下降,但无显著差异(P=0.861)。未报告严重不良事件。
我们的结果表明,艾司西酞普兰治疗强迫症的疗效与舍曲林相当。然而,需要注意的是,我们的研究是初步的,需要更大规模的双盲对照研究来证实这些结果。